PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same
The present invention relates to a complex of PPSA or PSPA polymer and a virus, and a pharmaceutical composition including the same. According to the present invention, when a polymer-virus complex formed using PPSA or PSPA polymer is used, transduction efficiency thereof to cells may be enhanced, an excellent therapeutic effect may thus be obtained when used as a pharmaceutical composition, and, therefore, the pharmaceutical agent may be useful as a therapeutic agent.
1. A bioreducible polymer represented by Formula 2,
where each of x and y independently is an integer from 1 to 5.
2. A polymer-virus complex in which the polymer of Formula 2 of claim 1 is bound to a surface of a virus.
3. The polymer-virus complex of claim 2 , wherein the virus is any one selected from the group consisting of adenovirus (Ads), adeno-associated virus (AAVs), retrovirus, lentivirus, herpes simplex virus and vaccinia virus.
4. The polymer-virus complex of claim 2 , wherein the virus is an Ad.
5. A pharmaceutical composition, comprising:
(a) the polymer-virus complex of claim 2 ; and
(b) a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 , wherein the composition further comprises a therapeutic gene.
7. The pharmaceutical composition of claim 5 , wherein the virus is any one selected from the group consisting of adenovirus (Ads), adeno-associated virus (AAVs), retrovirus, lentivirus, herpes simplex virus and vaccinia virus.
8. The pharmaceutical composition of claim 5 , wherein the virus is an Ad.
9. The pharmaceutical composition of claim 6 , wherein the therapeutic gene is a cancer-treating gene selected from the group consisting of a drug-sensitizing gene, a tumor suppressor gene, an antigenic gene, a cytokine gene, a cytotoxic gene, a cytostatic gene, a pro-apoptotic gene, and an anti-angiogenic gene.